Jared Gollob Kymera Therapeutics, Inc. (KYMR) insider trading activity

Jared Gollob is Chief Medical Officer of Kymera Therapeutics, Inc.. Currently has a direct ownership of 109,992 shares of KYMR, which is worth approximately $7.14 Million. The most recent transaction as insider was on Dec 08, 2025, when has been sold 49,307 shares (Common Stock) at a price of $89.77 per share, resulting in proceeds of $4,426,289. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 110K

8.34% 3M change

15.21% 12M change

Total Value Held $7.14 Million

Jared Gollob Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 08 2025	SELL Open market or private sale	$4,426,289 $89.77 p/Share	49,307 Reduced 30.95%	109,992 Common Stock
Dec 08 2025	BUY Exercise of conversion of derivative security	$262,806 $5.33 p/Share	49,307 Added 23.64%	159,299 Common Stock
Oct 15 2025	SELL Open market or private sale	$3,688,945 $61.92 p/Share	59,576 Reduced 35.13%	109,992 Common Stock
Oct 15 2025	BUY Exercise of conversion of derivative security	$87,055 $1.7 p/Share	51,209 Added 23.19%	169,568 Common Stock
Oct 13 2025	SELL Open market or private sale	$186,840 $60.0 p/Share	3,114 Reduced 2.56%	118,359 Common Stock
Oct 13 2025	BUY Exercise of conversion of derivative security	$2,504 $1.7 p/Share	1,473 Added 1.2%	121,473 Common Stock
Mar 03 2025	SELL Open market or private sale	$176,045 $30.67 p/Share	5,740 Reduced 4.56%	120,000 Common Stock

Mar 03 2025	BUY Grant, award, or other acquisition	-	30,000 Added 19.26%	125,740 Common Stock
Jul 16 2024	SELL Open market or private sale	$1,060,966 $45.84 p/Share	23,145 Reduced 19.51%	95,470 Common Stock
Jul 16 2024	BUY Exercise of conversion of derivative security	$48,141 $2.08 p/Share	23,145 Added 16.3%	118,885 Common Stock
Jul 15 2024	SELL Open market or private sale	$742,943 $45.15 p/Share	16,455 Reduced 14.67%	95,740 Common Stock
Jul 15 2024	BUY Exercise of conversion of derivative security	$34,226 $2.08 p/Share	16,455 Added 12.79%	112,195 Common Stock
Mar 04 2024	SELL Open market or private sale	$141,618 $42.35 p/Share	3,344 Reduced 3.37%	95,740 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	24,375 Added 19.74%	99,084 Common Stock
Feb 27 2024	SELL Open market or private sale	$18,000 $45.0 p/Share	400 Reduced 0.53%	74,709 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	$832 $2.08 p/Share	400 Added 0.53%	75,109 Common Stock
Feb 09 2024	SELL Open market or private sale	$1,648,936 $35.74 p/Share	46,137 Reduced 38.18%	74,709 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	$95,964 $2.08 p/Share	46,137 Added 27.63%	120,846 Common Stock
Mar 02 2023	SELL Open market or private sale	$40,419 $31.14 p/Share	1,298 Reduced 1.71%	74,709 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	18,750 Added 19.79%	76,007 Common Stock
May 04 2022	BUY Exercise of conversion of derivative security	$34,000 $1.7 p/Share	20,000 Added 25.89%	57,257 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	12,600 Added 25.27%	37,257 Common Stock
Nov 02 2021	SELL Open market or private sale	$953,446 $63.58 p/Share	14,996 Reduced 37.82%	24,657 Common Stock
Nov 02 2021	BUY Exercise of conversion of derivative security	$31,192 $2.08 p/Share	14,996 Added 27.44%	39,653 Common Stock
Nov 01 2021	SELL Open market or private sale	$2,628,439 $61.85 p/Share	42,497 Reduced 63.28%	24,657 Common Stock

Jared Gollob

Chief Medical Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KYMR shares.

Notify only if

Value

Insider Trading

Get notified when an Kymera Therapeutics, Inc. insider buys or sells KYMR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kymera Therapeutics, Inc.

Track Activities on KYMR

Account